Protein prenylation: Unique fats make their mark on biology

Nature Reviews Molecular Cell Biology

Volumn 17, Issue 2, 2016, Pages 110-122

  Wang, Mei ^a   Casey, Patrick J ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GERANYLGERANYLTRANSFERASE TYPE-I; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; P21(RAS) FARNESYL-PROTEIN TRANSFERASE; PROTEINASE; RAS PROTEIN; RCE1 PROTEIN, HUMAN; TERPENE; TRANSFERASE;

AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; PROTEIN PRENYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT;

AGING; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; PROTEIN PRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RAS PROTEINS; TERPENES;

EID: 84955654523     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm.2015.11     Document Type: Review

References (178)

1. Ambrogelly, A., Palioura, S. & Soll, D. Natural expansion of the genetic code. Nat. Chem. Biol. 3, 29-35 (2007).
2. Zhang, F. L. & Casey, P. J. Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269 (1996).
3. Gelb, M. H. et al. Therapeutic intervention based on protein prenylation and associated modifications. Nat. Chem. Biol. 2, 518-528 (2006).
4. Ashby, M. N. CaaX converting enzymes. Curr. Opin. Lipidol. 9, 99-102 (1998).
5. Winter-Vann, A. M. & Casey, P. J. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 5, 405-412 (2005).
6. Ahearn, I. M., Haigis, K., Bar-Sagi, D. & Philips, M. R. Regulating the regulator: Post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 13, 39-51 (2012).
7. Berndt, N., Hamilton, A. D. & Sebti, S. M. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775-791 (2011).
8. Schafer, W. R. & Rine, J. Protein prenylation: Genes, enzymes, targets, and functions. Annu. Rev. Genet. 26, 209-237 (1992).
9. Sinensky, M. et al. The processing pathway of prelamin A. J. Cell Sci. 107, 61-67 (1994).
10. Gordon, L. B., Rothman, F. G., Lopez-Otin, C. & Misteli, T. Progeria: A paradigm for translational medicine. Cell 156, 400-407 (2014).
11. Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 13, 828-851 (2014).
12. Kamiya, Y., Sakurai, A., Tamura, S. & Takahashi, N. Structure of rhodotorucine A, a novel lipopeptide, inducing mating tube formation in Rhodosporidium toruloides. Biochem. Biophys. Res. Commun. 83, 1077-1083 (1978).
13. Brown, M. S. & Goldstein, J. L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21, 505-517 (1980).
14. Quesney-Huneeus, V., Wiley, M. H. & Siperstein, M. D. Essential role for mevalonate synthesis in DNA replication. Proc. Natl Acad. Sci. USA 76, 5056-5060 (1979).
15. Habenicht, A. J., Glomset, J. A. & Ross, R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J. Biol. Chem. 255, 5134-5140 (1980).
16. Schmidt, R. A., Schneider, C. J. & Glomset, J. A. Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J. Biol. Chem. 259, 10175-10180 (1984).
17. Wolda, S. L. & Glomset, J. A. Evidence for modification of lamin B by a product of mevalonic acid. J. Biol. Chem. 263, 5997-6000 (1988).
18. Anderegg, R. J., Betz, R., Carr, S. A., Crabb, J. W. & Duntze, W. Structure of Saccharomyces cerevisiae mating hormone a-factor. Identification of S-farnesyl cysteine as a structural component. J. Biol. Chem. 263, 18236-18240 (1988).
19. Hancock, J. F., Magee, A. I., Childs, J. E. & Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57, 1167-1177 (1989).
20. Casey, P. J., Solski, P. A., Der, C. J. & Buss, J. E. p21ras is modified by a farnesyl isoprenoid. Proc. Natl Acad. Sci. USA 86, 8323-8327 (1989).
21. Schafer, W. R. et al. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245, 379-385 (1989).
22. Farnsworth, C. C., Gelb, M. H. & Glomset, J. A. Identification of geranylgeranyl-modified proteins in HeLa cells. Science 247, 320-322 (1990).
23. Mumby, S. M., Casey, P. J., Gilman, A. G., Gutowski, S. & Sternweis, P. C. G protein ? subunits contain a 20-carbon isoprenoid. Proc. Natl Acad. Sci. USA 87, 5873-5877 (1990).
24. Reid, T. S., Terry, K. L., Casey, P. J. & Beese, L. S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol. 343, 417-433 (2004).
25. Maurer-Stroh, S. et al. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput. Biol. 3, e66 (2007).
26. Hougland, J. L. et al. Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. J. Mol. Biol. 395, 176-190 (2010).
27. Armstrong, S. A., Seabra, M. C., Sudhof, T. C., Goldstein, J. L. & Brown, M. S. cDNA cloning and expression of the ? and ? subunits of rat Rab geranylgeranyl transferase. J. Biol. Chem. 268, 12221-12229 (1993).
28. Leung, K. F., Baron, R. & Seabra, M. C. Thematic review series: Lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J. Lipid Res. 47, 467-475 (2006).
29. Itzen, A. & Goody, R. S. GTPases involved in vesicular trafficking: Structures and mechanisms. Semin. Cell Dev. Biol. 22, 48-56 (2011).
30. Boyartchuk, V. L., Ashby, M. N. & Rine, J. Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 275, 1796-1800 (1997).
31. Dai, Q. et al. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J. Biol. Chem. 273, 15030-15034 (1998).
32. Hrycyna, C. A., Sapperstein, S. K., Clarke, S. & Michaelis, S. The Saccharomyces cerevisiae STE14 gene encodes a methyltransferase that mediates C-terminal methylation of a-factor and RAS proteins. EMBO J. 10, 1699-1709 (1991).
33. Kellogg, B. A. & Poulter, C. D. Chain elongation in the isoprenoid biosynthetic pathway. Curr. Opin. Chem. Biol. 1, 570-578 (1997).
34. Long, S. B., Casey, P. J. & Beese, L. S. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. Biochemistry 37, 9612-9618 (1998).
35. Long, S. B., Casey, P. J. & Beese, L. S. Reaction path of protein farnesyltransferase at atomic resolution. Nature 419, 645-650 (2002).
36. Furfine, E. S., Leban, J. J., Landavazo, A., Moomaw, J. F. & Casey, P. J. Protein farnesyltransferase: Kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 34, 6857-6862 (1995).
37. Taylor, J. S., Reid, T. S., Terry, K. L., Casey, P. J. & Beese, L. S. Structure of mammalian protein geranylgeranyltransferase type-I. EMBO J. 22, 5963-5974 (2003).
38. Zverina, E. A., Lamphear, C. L., Wright, E. N. & Fierke, C. A. Recent advances in protein prenyltransferases: Substrate identification, regulation, and disease interventions. Curr. Opin. Chem. Biol. 16, 544-552 (2012).
39. Hartman, H. L., Hicks, K. A. & Fierke, C. A. Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity. Biochemistry 44, 15314-15324 (2005).
40. Trueblood, C. E., Ohya, Y. & Rine, J. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae. Mol. Cell. Biol. 13, 4260-4275 (1993).
41. Sjogren, A. K. et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J. Clin. Invest. 117, 1294-1304 (2007).
42. Whyte, D. B. et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464 (1997).
43. Rao, S. et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 22, 3950-3957 (2004).
44. Du, W., Lebowitz, P. F. & Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19, 1831-1840 (1999).
45. Chen, Z. et al. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275, 17974-17978 (2000).
46. Zeng, P. Y., Rane, N., Du, W., Chintapalli, J. & Prendergast, G. C. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene 22, 1124-1134 (2003).
47. Sebti, S. M. & Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584-6593 (2000).
48. Berg, T. J. et al. Splice variants of SmgGDS control small GTPase prenylation and membrane localization. J. Biol. Chem. 285, 35255-35266 (2010).
49. Schuld, N. J. et al. The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motif. J. Biol. Chem. 289, 6862-6876 (2014).
50. Ntantie, E. et al. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci. Signal. 6, ra39 (2013).
51. Otto, J. C., Kim, E., Young, S. G. & Casey, P. J. Cloning and characterization of a mammalian prenyl protein-specific protease. J. Biol. Chem. 274, 8379-8382 (1999).
52. Boyartchuk, V. L. & Rine, J. Roles of prenyl protein proteases in maturation of Saccharomyces cerevisiae a-factor. Genetics 150, 95-101 (1998).
53. Kim, E. et al. Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J. Biol. Chem. 274, 8383-8390 (1999).
54. Tam, A. et al. Dual roles for Ste24p in yeast a-factor maturation: NH2-terminal proteolysis and COOH-terminal CAAX processing. J. Cell Biol. 142, 635-649 (1998).
55. Pendas, A. M. et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat. Genet. 31, 94-99 (2002).
56. Pillinger, M. H., Volker, C., Stock, J. B., Weissmann, G. & Philips, M. R. Characterization of a plasma membrane-associated prenylcysteine-directed ? carboxyl methyltransferase in human neutrophils. J. Biol. Chem. 269, 1486-1492 (1994).
57. Manolaridis, I. et al. Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1. Nature 504, 301-305 (2013).
58. Yang, J. et al. Mechanism of isoprenylcysteine carboxyl methylation from the crystal structure of the integral membrane methyltransferase ICMT. Mol. Cell 44, 997-1004 (2011).
59. Wright, L. P. et al. Topology of mammalian isoprenylcysteine carboxyl methyltransferase determined in live cells with a fluorescent probe. Mol. Cell. Biol. 29, 1826-1833 (2009).
60. Diver, M. M. & Long, S. B. Mutational analysis of the integral membrane methyltransferase isoprenylcysteine carboxyl methyltransferase (ICMT) reveals potential substrate binding sites. J. Biol. Chem. 289, 26007-26020 (2014).
61. Griggs, A. M., Hahne, K. & Hrycyna, C. A. Functional oligomerization of the Saccharomyces cerevisiae isoprenylcysteine carboxyl methyltransferase, Ste14p. J. Biol. Chem. 285, 13380-13387 (2010).
62. Plummer, L. J. et al. Mutational analysis of the ras converting enzyme reveals a requirement for glutamate and histidine residues. J. Biol. Chem. 281, 4596-4605 (2006).
63. Hildebrandt, E. R. et al. Topology of the yeast Ras converting enzyme as inferred from cysteine accessibility studies. Biochemistry 52, 6601-6614 (2013).
64. Hoffman, G. R., Nassar, N. & Cerione, R. A. Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell 100, 345-356 (2000).
65. Jaffe, A. B. & Hall, A. Rho GTPases: Biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21, 247-269 (2005).
66. Nishimura, A. & Linder, M. E. Identification of a novel prenyl and palmitoyl modification at the CaaX motif of Cdc42 that regulates RhoGDI binding. Mol. Cell. Biol. 33, 1417-1429 (2013).
67. Riou, P. et al. 14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins. Cell 153, 640-653 (2013).
68. Bhagatji, P., Leventis, R., Rich, R., Lin, C. J. & Silvius, J. R. Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane. Biophys. J. 99, 3327-3335 (2010).
69. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDE? interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
70. Ismail, S. A. et al. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nat. Chem. Biol. 7, 942-949 (2011).
71. Rotblat, B. et al. Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res. 64, 3112-3118 (2004).
72. Lopez-Alcala, C. et al. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J. Biol. Chem. 283, 10621-10631 (2008).
73. Figueroa, C., Taylor, J. & Vojtek, A. B. Prenylated Rab acceptor protein is a receptor for prenylated small GTPases. J. Biol. Chem. 276, 28219-28225 (2001).
74. Malumbres, M. & Barbacid, M. RAS oncogenes: The first 30 years. Nat. Rev. Cancer 3, 459-465 (2003).
75. Doll, R. J., Kirschmeier, P. & Bishop, W. R. Farnesyltransferase inhibitors as anticancer agents: Critical crossroads. Curr. Opin. Drug Discov. Devel. 7, 478-486 (2004).
76. Liu, M. et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc. Natl Acad. Sci. USA 107, 6471-6476 (2010).
77. Ashar, H. R. et al. The farnesyl transferase inhibitor SCH 66336 induces a G2 ? M or G1 pause in sensitive human tumor cell lines. Exp. Cell Res. 262, 17-27 (2001).
78. Crespo, N. C., Ohkanda, J., Yen, T. J., Hamilton, A. D. & Sebti, S. M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J. Biol. Chem. 276, 16161-16167 (2001).
79. Hussein, D. & Taylor, S. S. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J. Cell Sci. 115, 3403-3414 (2002).
80. Shimi, T. et al. The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev. 25, 2579-2593 (2011).
81. Adam, S. A., Butin-Israeli, V., Cleland, M. M., Shimi, T. & Goldman, R. D. Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors. Nucleus 4, 142-150 (2013).
82. Basso, A. D. et al. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 280, 31101-31108 (2005).
83. Houde, V. P. et al. Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using mouse knockin analysis reveals an unexpected role of prenylation in regulating AMPK activity. Biochem. J. 458, 41-56 (2014).
84. Hanker, A. B. et al. Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene 29, 380-391 (2010).
85. Li, X. et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 277, 15309-15316 (2002).
86. Peterson, Y. K., Kelly, P., Weinbaum, C. A. & Casey, P. J. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J. Biol. Chem. 281, 12445-12450 (2006).
87. Vasudevan, A. et al. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J. Med. Chem. 42, 1333-1340 (1999).
88. Lu, J. et al. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol. Cancer Ther. 8, 1218-1226 (2009).
89. Sun, J. et al. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J. Biol. Chem. 274, 6930-6934 (1999).
90. Dan, H. C. et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23, 706-715 (2004).
91. Morgan, M. A., Wegner, J., Aydilek, E., Ganser, A. & Reuter, C. W. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia 17, 1508-1520 (2003).
92. Bergo, M. O. et al. On the physiological importance of endoproteolysis of CAAX proteins: Heart-specific RCE1 knockout mice develop a lethal cardiomyopathy. J. Biol. Chem. 279, 4729-4736 (2004).
93. Christiansen, J. R., Kolandaivelu, S., Bergo, M. O. & Ramamurthy, V. RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segments. Proc. Natl Acad. Sci. USA 108, 8862-8866 (2011).
94. Bergo, M. O. et al. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J. Biol. Chem. 276, 5841-5845 (2001).
95. Lin, X. et al. Prenylcysteine carboxylmethyltransferase is essential for the earliest stages of liver development in mice. Gastroenterology 123, 345-351 (2002).
96. Smeland, T. E., Seabra, M. C., Goldstein, J. L. & Brown, M. S. Geranylgeranylated Rab proteins terminating in Cys-Ala-Cys, but not Cys-Cys, are carboxyl-methylated by bovine brain membranes in vitro. Proc. Natl Acad. Sci. USA 91, 10712-10716 (1994).
97. Wang, M. et al. A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. J. Biol. Chem. 283, 18678-18684 (2008).
98. Sane, K. M. et al. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. J. Pharmacol. Exp. Ther. 333, 23-33 (2010).
99. Pan, J., Song, E., Cheng, C., Lee, M. H. & Yeung, S. C. Farnesyltransferase inhibitors-induced autophagy: Alternative mechanisms? Autophagy 5, 129-131 (2009).
100. Zhu, W. L. et al. A role for Rac3 GTPase in the regulation of autophagy. J. Biol. Chem. 286, 35291-35298 (2011).
101. Kim, Y. C. & Guan, K. L. mTOR: A pharmacologic target for autophagy regulation. J. Clin. Invest. 125, 25-32 (2015).
102. Levine, B. & Kroemer, G. Autophagy in aging, disease and death: The true identity of a cell death impostor. Cell Death Differ. 16, 1-2 (2009).
103. Teh, J. T. et al. Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism. Oncogene 34, 3296-3304 (2014).
104. Backlund, P. S. Jr. Post-translational processing of RhoA. Carboxyl methylation of the carboxyl-terminal prenylcysteine increases the half-life of RhoA. J. Biol. Chem. 272, 33175-33180 (1997).
105. Bergo, M. O. et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J. Clin. Invest. 113, 539-550 (2004).
106. Heasman, S. J. & Ridley, A. J. Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 9, 690-701 (2008).
107. Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559-1564 (2011).
108. Cushman, I. & Casey, P. J. Role of isoprenylcysteine carboxylmethyltransferase-catalyzed methylation in Rho function and migration. J. Biol. Chem. 284, 27964-27973 (2009).
109. Michaelson, D. et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol. Biol. Cell 16, 1606-1616 (2005).
110. Stubbs, E. B. Jr & Von Zee, C. L. Prenylation of Rho G-proteins: A novel mechanism regulating gene expression and protein stability in human trabecular meshwork cells. Mol. Neurobiol. 46, 28-40 (2012).
111. Lu, Q. et al. Isoprenylcysteine carboxyl methyltransferase modulates endothelial monolayer permeability. Involvement of RhoA carboxyl methylation. Circ. Res. 94, 306-315 (2004).
112. Cushman, I., Cushman, S. M., Potter, P. M. & Casey, P. J. Control of RhoA methylation by carboxylesterase I. J. Biol. Chem. 288, 19177-19183 (2013).
113. Oboh, O. T. & Lamango, N. S. Liver prenylated methylated protein methyl esterase is the same enzyme as Sus scrofa carboxylesterase. J. Biochem. Mol. Toxicol. 22, 51-62 (2008).
114. Deem, A. K., Bultema, R. L. & Crowell, D. N. Prenylcysteine methylesterase in Arabidopsis thaliana. Gene 380, 159-166 (2006).
115. Huizinga, D. H., Omosegbon, O., Omery, B. & Crowell, D. N. Isoprenylcysteine methylation and demethylation regulate abscisic acid signaling in Arabidopsis. Plant Cell 20, 2714-2728 (2008).
116. Cox, A. D., Der, C. J. & Philips, M. R. Targeting RAS membrane association: Back to the future for anti-RAS drug discovery? Clin. Cancer Res. 21, 1819-1827 (2015).
117. Gibbs, J. B., Oliff, A. & Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77, 175-178 (1994).
118. Sousa, S., Fernandes, P. & Ramos, M. Farnesyltransferase inhibitors: A detailed chemical view on an elusive biological problem. Curr. Med. Chem. 15, 1478-1492 (2008).
119. Karp, J. E. & Lancet, J. E. Development of farnesyltransferase inhibitors for clinical cancer therapy: Focus on hematologic malignancies. Cancer Invest. 25, 484-494 (2007).
120. Tsimberidou, A. M., Chandhasin, C. & Kurzrock, R. Farnesyltransferase inhibitors: Where are we now? Expert Opin. Investig. Drugs 19, 1569-1580 (2010).
121. Kohl, N. E. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1, 792-797 (1995).
122. Chen, X., Makarewicz, J. M., Knauf, J. A., Johnson, L. K. & Fagin, J. A. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene 33, 5442-5449 (2014).
123. Schmidmaier, R. et al. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104, 1825-1832 (2004).
124. Falsetti, S. C. et al. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol. Cell. Biol. 27, 8003-8014 (2007).
125. Park, H. J. et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 91, 143-150 (2002).
126. Kusama, T. et al. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin. Exp. Metastasis 20, 561-567 (2003).
127. Hasan, Z. et al. Geranylgeranyl transferase regulates CXC chemokine formation in alveolar macrophages and neutrophil recruitment in septic lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L221-L229 (2013).
128. Khan, O. M. et al. Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. J. Clin. Invest. 121, 628-639 (2011).
129. Jain, M. K. & Ridker, P. M. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977-987 (2005).
130. Bergo, M. O. et al. Absence of the CAAX endoprotease Rce1: Effects on cell growth and transformation. Mol. Cell. Biol. 22, 171-181 (2002).
131. Wahlstrom, A. M. et al. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease. Blood 109, 763-768 (2007).
132. Wahlstrom, A. M. et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 112, 1357-1365 (2008).
133. Court, H. et al. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J. Clin. Invest. 123, 4681-4694 (2013).
134. Winter-Vann, A. M. et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl Acad. Sci. USA 102, 4336-4341 (2005).
135. Donelson, J. L. et al. Amide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase. Bioorg. Med. Chem. Lett. 16, 4420-4423 (2006).
136. Judd, W. R. et al. Discovery and SAR of methylated tetrahydropyranyl derivatives as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT). J. Med. Chem. 54, 5031-5047 (2011).
137. Bergman, J. A., Hahne, K., Song, J., Hrycyna, C. A. & Gibbs, R. A. S-farnesyl-thiopropionic acid (FTPA) triazoles as potent inhibitors of isoprenylcysteine carboxyl methyltransferase. ACS Med. Chem. Lett. 3, 15-19 (2012).
138. Wang, M. et al. Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth. Oncogene 29, 4959-4970 (2010).
139. Lau, H. Y. et al. An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. Cancer Biol. Ther. 15, 1280-1291 (2014).
140. Cao, K. et al. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J. Clin. Invest. 121, 2833-2844 (2011).
141. Capell, B. C. et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl Acad. Sci. USA 102, 12879-12884 (2005).
142. Yang, S. H. et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J. Clin. Invest. 116, 2115-2121 (2006).
143. Leung, G. K. et al. Biochemical studies of Zmpste24-deficient mice. J. Biol. Chem. 276, 29051-29058 (2001).
144. Young, S. G., Meta, M., Yang, S. H. & Fong, L. G. Prelamin A farnesylation and progeroid syndromes. J. Biol. Chem. 281, 39741-39745 (2006).
145. Navarro, C. L. et al. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of lamin A precursors. Hum. Mol. Genet. 14, 1503-1513 (2005).
146. Moulson, C. L. et al. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J. Invest. Dermatol. 125, 913-919 (2005).
147. Broers, J. L., Ramaekers, F. C., Bonne, G., Yaou, R. B. & Hutchison, C. J. Nuclear lamins: Laminopathies and their role in premature ageing. Physiol. Rev. 86, 967-1008 (2006).
148. Fong, L. G. et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311, 1621-1623 (2006).
149. Yang, S. H. et al. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum. Mol. Genet. 20, 436-444 (2011).
150. Gordon, L. B. et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 130, 27-34 (2014).
151. Ibrahim, M. X. et al. Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science 340, 1330-1333 (2013).
152. Ye, X. & Carew, T. J. Small G protein signaling in neuronal plasticity and memory formation: The specific role of ras family proteins. Neuron 68, 340-361 (2010).
153. Samuel, F. et al. Inhibiting geranylgeranylation increases neurite branching and differentially activates cofilin in cell bodies and growth cones. Mol. Neurobiol. 50, 49-59 (2014).
154. Hottman, D. A. & Li, L. Protein prenylation and synaptic plasticity: Implications for Alzheimer's disease. Mol. Neurobiol. 50, 177-185 (2014).
155. Cheng, S. et al. Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease. J. Biol. Chem. 288, 35952-35960 (2013).
156. Ye, J. et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl Acad. Sci. USA 100, 15865-15870 (2003).
157. Hannoush, R. N. & Sun, J. The chemical toolbox for monitoring protein fatty acylation and prenylation. Nat. Chem. Biol. 6, 498-506 (2010).
158. Palsuledesai, C. C., Ochocki, J. D., Markowski, T. W. & Distefano, M. D. A combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins. Mol. Biosyst. 10, 1094-1103 (2014).
159. Duckworth, B. P., Zhang, Z., Hosokawa, A. & Distefano, M. D. Selective labeling of proteins by using protein farnesyltransferase. ChemBioChem 8, 98-105 (2007).
160. Nguyen, U. T. et al. Analysis of the eukaryotic prenylome by isoprenoid affinity tagging. Nat. Chem. Biol. 5, 227-235 (2009).
161. Soltis, D. A. et al. Expression, purification, and characterization of the human squalene synthase: Use of yeast and baculoviral systems. Arch. Biochem. Biophys. 316, 713-723 (1995).
162. Sagami, H., Morita, Y. & Ogura, K. Purification and properties of geranylgeranyl-diphosphate synthase from bovine brain. J. Biol. Chem. 269, 20561-20566 (1994).
163. McFarlane, S. I., Muniyappa, R., Francisco, R. & Sowers, J. R. Clinical review 145: Pleiotropic effects of statins: Lipid reduction and beyond. J. Clin. Endocrinol. Metab. 87, 1451-1458 (2002).
164. Hooff, G. P., Wood, W. G., Muller, W. E. & Eckert, G. P. Isoprenoids, small GTPases and Alzheimer's disease. Biochim. Biophys. Acta 1801, 896-905 (2010).
165. Mammen, A. L. & Amato, A. A. Statin myopathy: A review of recent progress. Curr. Opin. Rheumatol. 22, 644-650 (2010).
166. Lee, M. H., Cho, Y. S. & Han, Y. M. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Stem Cells 25, 1654-1663 (2007).
167. Waiczies, S. et al. Geranylgeranylation but not GTP loading determines rho migratory function in T cells. J. Immunol. 179, 6024-6032 (2007).
168. Zhao, T. T. et al. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: Potential regulation by targeting rho proteins. Oncogene 29, 4682-4692 (2010).
169. Sorrentino, G. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 16, 357-366 (2014).
170. Wrighton, K. H. Metabolism: YAP and TAZ under metabolic control. Nat. Rev. Mol. Cell Biol. 15, 296 (2014).
171. Eastman, R. T., Buckner, F. S., Yokoyama, K., Gelb, M. H. & Van Voorhis, W. C. Thematic review series: Lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J. Lipid Res. 47, 233-240 (2006).
172. Hast, M. A. et al. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem. Biol. 16, 181-192 (2009).
173. Glenn, J. S., Watson, J. A., Havel, C. M. & White, J. M. Identification of a prenylation site in delta virus large antigen. Science 256, 1331-1333 (1992).
174. Otto, J. C. & Casey, P. J. The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. J. Biol. Chem. 271, 4569-4572 (1996).
175. Bordier, B. B. et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J. Clin. Invest. 112, 407-414 (2003).
176. Wedemeyer, H. & Manns, M. P. Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nat. Rev. Gastroenterol. Hepatol. 7, 31-40 (2010).
177. Koh, C. et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect. Dis. 15, 1167-1174 (2015).
178. Wang, C. et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol. Cell 18, 425-434 (2005).